ACP Journal Club. HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women.
作者信息
Budenholzer Brian
出版信息
Ann Intern Med. 2012 Jul 17;157(2):JC2-6, JC2-7. doi: 10.7326/0003-4819-157-2-201207170-02007.
Abstract
摘要
相似文献
1
ACP Journal Club. HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women.《美国内科医师学会杂志俱乐部》。人乳头瘤病毒16/18 AS04佐剂疫苗预防年轻女性宫颈上皮内瘤变≥3级。
Ann Intern Med. 2012 Jul 17;157(2):JC2-6, JC2-7. doi: 10.7326/0003-4819-157-2-201207170-02007.
2
ACP Journal Club. Human papillomavirus 16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia in young women.《美国内科医师学会杂志俱乐部》。人乳头瘤病毒16/18 AS04佐剂疫苗预防年轻女性宫颈上皮内瘤变。
Ann Intern Med. 2009 Dec 15;151(12):JC6-6. doi: 10.7326/0003-4819-151-12-200912150-02006.
3
AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.AS04佐剂人乳头瘤病毒16/18疫苗接种：宫颈癌预防的最新进展
Expert Rev Vaccines. 2008 Dec;7(10):1465-73. doi: 10.1586/14760584.7.10.1465.
4
A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.人乳头瘤病毒16/18 AS04佐剂宫颈癌疫苗对致癌性人乳头瘤病毒的交叉保护作用综述：病毒学和临床终点的重要性及其对宫颈癌预防大规模疫苗接种的影响
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S18-25. doi: 10.1016/j.ygyno.2008.06.027. Epub 2008 Jul 23.
5
Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.AS04 佐剂人乳头瘤病毒 16/18 型宫颈癌疫苗（佳达修）的临床更新。
Adv Ther. 2009 Nov;26(11):983-98. doi: 10.1007/s12325-009-0079-5. Epub 2009 Dec 18.
6
ACP Journal Club. Adding HPV testing to cytology screening reduced ≥ grade 3 cervical intraepithelial neoplasia at 5 years.《美国内科医师学会杂志俱乐部》。在细胞学筛查中增加人乳头瘤病毒检测可在5年内降低≥3级宫颈上皮内瘤变的发生率。
Ann Intern Med. 2012 Jul 17;157(2):JC2-6, JC2-7. doi: 10.7326/0003-4819-157-2-201207170-02006.
7
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.人乳头瘤病毒16/18 AS04佐剂宫颈癌疫苗在健康印度女性中的免疫原性和安全性
J Obstet Gynaecol Res. 2010 Feb;36(1):123-32. doi: 10.1111/j.1447-0756.2009.01167.x.
8
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.HPV-16/18 AS04 佐剂疫苗在年轻成年女性中长达 7.3 年的持续疗效和免疫原性。
Vaccine. 2010 Aug 31;28(38):6247-55. doi: 10.1016/j.vaccine.2010.07.007. Epub 2010 Jul 17.
9
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.接种含AS04佐剂的宫颈癌疫苗诱导产生的抗人乳头瘤病毒16型和18型抗体的长期持续性：持续抗体反应的模型
Gynecol Oncol. 2009 Dec;115(3 Suppl):S1-6. doi: 10.1016/j.ygyno.2009.01.011. Epub 2009 Feb 12.
10
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.一项关于人乳头瘤病毒感染与2级或3级宫颈上皮内瘤变风险的队列研究。
N Engl J Med. 1992 Oct 29;327(18):1272-8. doi: 10.1056/NEJM199210293271804.
Zotero 插件